GMED GMED グロ―バス・メディカル



symbol GMED
会社名 Globus Medical Inc (GMED グロ―バス・メディカル)
業種 医療機器_医療用品_ディストリビュ―タ―   医療関連(Health Care)
概要 事業概要 グロバス・メディカル(Globus Medical Inc.)は医療機器会社である。同社は筋骨格系障害患者向け製品を開発する。同社は脊椎疾患患者の治療を中心とする。同社の製品は革新的融合技術と破壊的技術を含む。革新的融合技術製品には脊椎全体の脊髄障害を治療するための融合製品が含まれ、外科的アプローチで使用できる。破壊的技術製品は外科的処置と脊髄障害の治療を可能にすることによって、脊髄障害の治療における変化を表す。QUARTEXは、Occipito-Cervico-Thoracic(OCT)安定化システムである。QUARTEXは低トルクを可能にするネジロックキャップを有する。同社のパイプライン・ディスラプティブ・テクノロジー製品ポートフォリオには最小侵襲外科(MIS)技術を可能にする製品が含まれる。  グロ―バス・メディカルは米国の医療機器メ―カ―。脊椎疾患治療を中心に製品を開発、製造、販売する。同社の製品は革新的融合技術製品と破壊的技術製品の2分野に分類され、製品には脊椎固定機器「カリバ―」、頚椎固定用プレ―ト「アシュア」、椎弓形成術用器具「キャノピ―」などがある。  Based in Audubon, Pennsylvania, Globus Medical, Inc. was founded in 2003 by an experienced team of professionals with a shared vision to create products that enable surgeons to promote healing in patients with musculoskeletal disorders.
本社所在地 610 930-1800
代表者氏名 David C. Paul
代表者役職名 Executive Chairman of the Board
電話番号 +1 610-930-1800
設立年月日 37681
市場名 NYSE(ニューヨーク証券取引所)
従業員数 1800人
EBITDA EBITDA(百万ドル) 218.51200
時価総額 時価総額(百万ドル) 4874.46700
売上高 売上高(百万ドル) 712.96900
企業価値(EV) 企業価値(EV)(百万ドル) 4534.78300
当期純利益 当期純利益(百万ドル) 156.47300
決算概要 決算概要 BRIEF: For the fiscal year ended 31 December 2018 Globus Medical Inc revenues increased 12% to $713M. Net income before extraordinary items increased 32% to $156.5M. Revenues reflect United States segment increase of 12% to $593.9M International segment increase of 12% to $119.1M. Net income benefited from Interest income net increase from $6.6M to $13.3M (income) Other income/(loss) increase from $571K to $5.6M (income).



   Globus Medical, Nuvasive shareholders approve $3.1B merger deal  2023/04/28 16:31:57 Business Journals
When the merger closes, Globus shareholders will own about 72% of the combined company.
   Globus Medical Shareholders Approve Share Issuance for Merger with NuVasive  2023/04/27 23:08:14 Benzinga
AUDUBON, Pa., April 27, 2023 (GLOBE NEWSWIRE) -- Globus Medical , Inc. (NYSE: GMED ), a leading musculoskeletal solutions company, today announced that at the special meeting of shareholders held earlier today its shareholders voted to approve the issuance of shares of Globus Medical Class A common stock in connection with the proposed merger with NuVasive (NASDAQ: NUVA ). As previously announced, under the terms of the merger agreement, Globus Medical will issue 0.75 of a share of Globus Medical Class A common stock in exchange for each share of NuVasive common stock owned at the closing of the transaction. "Globus Medical shareholders showed an overwhelming level of support for this merger," said Dan Scavilla, president and CEO of Globus Medical. "Globus Medical and NuVasive are committed to providing innovative technologies and industry leading clinical support to help surgeons and healthcare providers deliver continually improving care. Our combined company will have one of the most comprehensive offerings of musculoskeletal solutions and enabling technologies to help surgeons treat their patients.
   NuVasive merger with Globus Medical approved by shareholders  2023/04/27 21:06:24 Seeking Alpha
NuVasive (NUVA) shareholders have approved the company''s planned merger with Globus Medical (GMED). Read more here.
   7 Stocks to Buy with Bulletproof Balance Sheets  2023/04/17 23:22:34 InvestorPlace
With a recession possibly on the horizon, investors may want to consider acquiring stocks with strong balance sheets. Of course, the underlying topic features much debate. According to a Reuters report, the Bank of Canada noted that the risk of recession shrunk . On the other hand, Morgan Stanley reported that U.S. recession risks were rising prior to the banking sector meltdown. It’s hard to imagine that bank runs and the failures of two major financial institutions assuage these concerns. Therefore, it’s well worth considering stocks with solid financials. Further, an important component undergirding stocks with resilient balance sheets centers on participation. Here, we’re not talking about abandoning the equities market altogether. For full disclosure, that would be bad for my business. Rather, we’re simply considering adjusting portfolios to reflect certain realities. Each of the companies below have been screened for a minimum of 2:1 for quick and cash ratios. As well, none have long-term debt on their books.
   Glass Lewis Recommends NuVasive Shareholders Vote "FOR" the Proposed Merger with Globus Medical  2023/04/17 18:00:02
   Global and United States Vertebroplasty and Kyphoplasty Device Market to Witness Huge Growth by Key Players: Stryker, Globus Medical, Merit Medical Systems, BMK Global Medical Company, Zavation, Spine Wave  2022/12/20 08:50:47 OpenPR
The Vertebroplasty and Kyphoplasty Device market research report delivers accurate data and innovative corporate analysis, helping organizations of all sizes make appropriate decisions. The Vertebroplasty and Kyphoplasty Device report also incorporates the current and future global market outlook in the
   Spine Surgery Market 2022 Key Stakeholders, CAGR, Growth Factors and Forecast 2028 | DePuy Synthes, Medtronic, Stryker, Zimmer-Biomet, Abbott Laboratories, Globus Medical Inc  2022/12/02 06:40:09 OpenPR
The Spine Surgery Market report will help you discover potential markets for new product launches and the best way to distribute a certain product. To understand all the above aspects, a formal management approach is taken to do the same.
   Globus Medical: Retain Buy With EPS Upside, Seeking Objectives Of $86, $106 (NYSE:GMED)  2022/11/18 10:46:48 Seeking Alpha
Globus Medical is positioned to deliver tremendous EPS upside over the coming 3 quarters in our estimation. Click here for a full investment analysis of GMED stock.
   Globus Medical: Reacceleration And Innovation Continue To Drive Growth (NYSE:GMED)  2022/11/17 20:20:35 Seeking Alpha
Globus showed reacceleration and share growth in the U.S. spine market in the third quarter, as technology (robotics, imaging/navigation) continues to drive implant share growth.
   Globus Medical PT Raised to $68 at Morgan Stanley  2022/11/09 10:18:20
   Orthopedic Implants Market Size Worth $67.23 Billion, Globally, by 2028 at 5.6% CAGR - Exclusive Research Report by The Insight Partners  2022/09/28 11:30:00 Benzinga
NEW YORK , Sept. 28, 2022 /PRNewswire/ -- The Insight Partners published latest research study on " Orthopedic Implants Market Size, Share, Revenue, Growth Strategy, Industry Trends and Forecast to 2028 - COVID-19 Impact and Global Analysis by Product, Application, End User, and Geography", the global orthopedic implants market size is expected to grow from $46.10 Billion in 2021 to $67.23 Billion by 2028; it is expected to grow at a CAGR of 5.6% from 2022 to 2028. Download Sample Brochure of Orthopedic Implants Market Size - COVID-19 Impact and Global Analysis with Strategic Insights at: Orthopedic Implants Market Report Scope, Segmentations, Regional & Country Scope: Report Coverage Details Market Size Value in US$ 46.10 Billion in 2021 Market Size Value by US$ 67.23 Billion by 2028 Growth rate CAGR of 5.6% from 2022 to 2028 Forecast Period 2022-2028 Base Year 2021 No. of Pages 150 Historical data available Yes Segments covered Product, Application, End User, and Geography Regional scope North America; Europe; Asia Pacific; Latin America; MEA Country scope US, UK, Canada, Germany, France, Italy, Australia, Russia, China, Japan, South Korea, Saudi Arabia, Brazil, Argentina Report coverage Revenue forecast, company ranking, competitive landscape, growth factors, and trends Companies Covered DJO Finance LLC; Johnson & Johnson (DePuy Synthes); Medtronic Plc; Zimmer Biomet Holdings, Inc.; Stryker Corporation; NuVasive, Inc.; CONMED Corporation; Smith and Nephew Plc; Arthrex, Inc.; Globus Medical, Inc.
   What Does 2022 Hold For Globus Medical Inc. (NYSE:GMED)?  2022/09/10 14:30:00 Stocks Register
Globus Medical Inc. (NYSE:GMED) price on Friday, September 09, rose 2.82% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $62.81. A look at the stock’s price movement, the close in the last trading session was $61.09, moving within a range at $61.09 and $62.93. The beta value … What Does 2022 Hold For Globus Medical Inc. (NYSE:GMED)? Read More »
   Could Globus Medical Be the Best Healthcare Stock?  2022/09/06 14:00:00 The Motley Fool
Globus Medical makes surgery faster and safer.
   Globus Medical PT Lowered to $71 at BTIG  2022/08/05 10:01:11
   Globus Medical (GMED) Q2 2022 Earnings Call Transcript  2022/08/05 03:30:32 The Motley Fool
GMED earnings call for the period ending June 30, 2022.

 関連キーワード  (医療機器_医療用品_ディストリビュ―タ― 米国株 GMED グロ―バス・メディカル GMED )


 twitter  (公式ツイッターやCEOツイッターなど)